dc.description.abstract | Panax notoginseng (Burk.) F. H. Chen, is one of the most famous traditional Chinese medicines. It belongs to the Araliaceae family. Its medicinal properties are sweet and slightly bitter in flavor and warm in nature. The main bioactive compound was regarded as saponins, and was used for treatment of diseases of cardiovascular, central nervous, and hematopoietic systems. Cancer prevention and hepatoprotection by saponins have received increasing attention. It has been found that the ginsenosides could be transformed by human intestinal bacteria to metabolites with improvement of anti-carcinogenic activities. Biotransformation of saponins of P. notoginseng by lactic acid bacteria (LAB) is a possible way to enhance its anti-hepatoma activity. The objectives of this study are (1) to establish the optimal conditions, such as fermentation time, temperature and pH value, for the lactic acid fermentation of P. notoginseng, to enhance the anti-hepatoma function of the fermented products; (2) to investigate the bioactive components in the fermentation products which are responsible for the anti-hepatoma activity; (3) to elucidate the inhibitory effect of the fermented products on the growth of hepatoma cells by means of in vitro and in vivo studies.
The present study established the optimal fermentation conditions for the inhibitory effects of fermentative broth on hepatoma cells. The best inhibitory effects were reached after fermentation with LAB for 48 hours at 37℃, and leaving the pH value uncontrolled when carrying out the fermentation in a 6.6 liter bioreactor. The IC50 of Hep 3B and Hep G2 were 226 μg/ml and 149 μg/ml, respectively. Meanwhile, the identification of the saponins in the fermentative broth of P. notoginseng
was elucidated by using LC–ESI-MS/ MS and CID. Based on matching their detection of the saponin molecular weight, and the fragment ions of the molecular ion obtained in the CID experiments with data reported in the literature. Further study will focus on the animal experiments. | en |
dc.relation.reference | 高成芝。1985。中藥三七原植物的訂正。中藥通報 10: 13-15。
趙國強、王秀訓。1986。三七止血成分Dencichine。中草藥 17: 34。
溫尚開、韦家福。1987。三七及其偽品的比較鑑定。藥學通報 22: 526-528。
張穗。1989。熟三七炮製法的研究。中成藥 11: 20-21。
唐第光。1991。三七炮製方法研究-油炸法。中成藥 13: 18-19。
李秉進。1993。SCID MICE簡介。國家實驗動物繁殖及研究中心簡訊 1:1。
林曙光。1993。三七皂甙對高脂血清所致的培養主動脈平滑肌細胞增殖的作用。中國藥理學報 14: 314。
王一菱、陳迪、吳景兰。1994。三七總皂甙抗炎和陣痛作用及其機理探討。中國中西醫結合雜誌 14: 35。
楊培銘。1994。肝與肝炎。健康世界雜誌社,台北。
胡學如、蔡慶宜、黃勝煌。1996。實驗動物技術人員訓練手冊二版。行政院國家科學委員會國家實驗動物繁殖及研究中心。
馮培芳、秦南屏、喬樵等。1997。三七總皂甙改善高血壓病左室舒張功能的臨床與實驗研究。中國中西醫結合雜誌 17: 714。
徐皓亮、季勇、饒曼人。1998。三七皂甙Rg1對大鼠實驗性血栓形成、血小板聚集率及血小板內游離鈣水平的影響。中國藥理學與毒理學雜誌 12: 40。
馬丽焱、王春兰、張琪等。1998。三七皂甙對腦組織血液供應和能量代謝的影響。中國藥理學通報 14: 27。
馬丽焱、肖培根。1998。三七總皂甙對突觸體谷氨酸瘦體特異性結合的影響。中國藥理學通報 14: 311。
李淑慧、楚延。1999。三七總皂苷的抗炎作用。中國藥理學學報 20: 554。譚健民。1999。肝功能異常時該怎麼辦?生智文化事業有限公司,台北。
曾岐原。1999。最新病理學,第二版。匯華圖書出版有限公司。台北,台灣。
王兴紅、李祺德、曹秋娥。2001。微生物發酵中藥應成為中藥研究的新內容。中草藥 32: 267-168。
和信治癌中心醫院。2001。肝病三部曲。天下生活出版股份有限公司,台北。
張嘉麟、徐文安、吳双凤、鮮穗江、翁稚穎、楊萌康。2001。三七中人參皂甙對老年鼠血漿脂質及其代謝產物含量的影響。昆明醫學院學報 22: 45。
馬吉生、周秋麗、費曉方、孫曄、王本樣。2001。真菌對人蔘皂苷Rb1及人蔘二醇系皂苷的代謝作用。藥學學報 36: 603-605。
雷秀玲、董雪峰、陳植和等。2001。絡泰對大鼠實驗性急性心肌缺血的保護作用及抗脂質過氧化作用。天然產物研究與開發 13: 58。
吳兰鸥、吳平、陆英等。2002。三七總皂甙Rg1對抗化學性記憶障礙的實驗研究。雲南中醫中藥雜誌 23: 36。
邱哲琳2002。核苷誘導人類肝癌細胞株Hep G2與Hep 3B細胞程式凋亡之影響。台北醫學大學保健營養所碩士論文。
崔秀明、董婷霞、黃文哲、陳中堅、詹華強。2002。三七中黃酮成分的含量測定。中草藥 33: 611-612。
李平兰、时向东、呂燕妮、江志杰、沈清武、马长伟。2003。常見中草藥對兩種腸道有益菌體外生長的影響。中國農業大學學報 8: 33-36。
陳悅穎。2003。人蔘苷苷Rh2抗癌活性的研究。國立成功大學藥理學研究所碩士論文。
張繼、趙朝伟、趙睿。2003。三七的藥理作用研究進展。中國藥業 12: 76-77。
王國俊、周黎明、王莉、陶大昌、朱玲。2004。三七皂苷R1誘導HL-60細胞凋亡的初步研究。四川生理科學雜誌 26: 14-16。
陳伯珠。2004。一、高通量篩選出牛樟芝菌絲體抗肝癌先導藥物化合物;二、以p53. bax. Bcl-2之m-RNA層次進行抗肝癌先導華物化合物對人類肝癌細胞株HenG2凋亡途徑之探討。國立中正大學化學研究所碩士論文。
石小楓、徐曼、劉杞。三七總皂甙對肝纖維化大鼠I、III型膠原及TGF-ß1的影響。中藥藥理與臨床 17: 7。
郭明良。2005。健康食品之降低癌症發生率功能評估方法草案。
Akao T. 1992. Metabolic activation of crude drug components by intestinal bacterial enzymes. J. Med. Pharm. Soc. 9: 1-13.
Akao T, Che QM, Kobashi K, Yang L, Hattori M, and Namba T. 1994. Isolation of a human intestinal anaerobe, Biffidobacterium sp. strain SEN, capable of hydrolyzing sennosides to sennidins. Appl. Environ. Microbiol. 60: 1041-1043.
Akao T, Kida H, Kanaoka M, Hattori M, and Kobashi K. 1998. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J. Pharm. Pharmacol. 50:1155-1160.
Bae EA, Han MJ, Choo MK, Park SY, and Kim DH. 2002. Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol. Pharm. Bull. 25: 58-63.
Bae EA, Park SY, and Kim DH. 2000. Constitutive β-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol. Pharm. Bull. 23: 1481-1485.
Bae EH, Han MJ, Kim EU, and Kim DH. 2004. Transformation of ginseng saponins to ginsenosides Rh2 by acid and human intestinal bacteria and biological activities of their transformants. Arch. Pharm. Res. 27(1):61-7.
Border WA, and Noble NA. 1994. Transforming growth factorin tissue fibrosis. N. Engl. J. Med. 331(19): 1286-92.
Bosma GC, Custer RP, Bosma MJ. 1983. A severe combined immunodeficiency mutation in the mouse. Nature 301:527-30.
Bristow MR, Billingham ME, Mason JW, and Daniels JR. 1978. Clinical spectrum of anthracycline cardiotoxicity. Cancer Treat Rep. 62: 873-879.
Bustos G, Moldes AB, Cruz JM, and Domínguez JM. 2004. Formulation of low-cost fermentative media for lactic acid production with Lactobacillus rhamnosus using vinification lees as nutrients. J. Agric. Food Chem. 52: 801-808.
Carr BI. 2004. Hepatocellur carcinoma: current management and future trends. Gastroenterology. 127: s218-s224.
Castaňeda F and Kinne RKH. 1999. Effects of doxorubicin, mitomycin C, and ethanol on Hep-G2 cells in vitro. J. Cancer Res. Clin. Oncol. 125: 1-8.
Chan P, Thomas GN, Tomlinson B. 2002. Protective effect of trilinolein extracted from Panax notoginseng against cardiovascular disease. Acta. Pharmacol. Sin. 23:1157-1162.
Chan WY, Chau FT, Lee KK, Kwong WH, and Yew DT. 2004. Substitution for natural musk in Pien Tze Huang does not affect its hepatoprotective activities. Hum Exp Toxicol. 23:35-47.
Chen JC, Tsai CC, Chen LD, Chen HH, and Wang WC. 2000. Therapeutic effects of gypenoside on chronic liver injury and fibrosis induced by CCl4 in rats. Amer. J. Chin. Med. 28:175–185.
Chen JQ, Zhang YG, Li SL, Zeng Q and Rong MZ. 1994. Effects of Panax notoginseng saponins on myocardial adenosine triphosphatase. Acta Pharmacological Sinica. 15: 347-350.
Choi SS, Lee JK, Han EJ, Han KJ, Lee HK, Lee Jongho, and Suh HW. 2003. Effect of ginsenoside Rd on nitric oxide system induced by lipopolysaccharide plus TNF-α in C6 rat glioma cells. Arch. Pharm. Res. 26: 375-382.
Confer DR and Logan BE. 1991. Increased bacterial uptake of macromolecular substrates with fluid shear. Appl. Environ. Microbiol. 57: 3093-3100.
Dong Tina TX, Cui XM, Song ZH, Zhao KJ, Ji ZN, Lo CK, and Tsim Karl WK. 2002. Chemical assessment of roots of Panax notoginseng in China: regional and seasonal variations in its active constituents. J. Agric. Food Chem. 51: 4617-4623.
Fátima Silva Lopes M, Cunha AE, Clemente JJ, Teixeira Carrondo MJ, and Barreto Crespo MT. 1999. Influence of environmental factors on lipase production by Lactobacillus plantarum. Appl. Microbiol. Biotechnol. 51: 249-254.
Fei XF, Wang BX, Tashiro S, Li TJ, Ma JS, and Ikejima T. 2002. Apoptotic effects of ginsenoside Rh2 on human malignant melanoma A375-S2 cells. Acta. Pharmacol. Sin. 23: 315-322.
Fisher DE. 1994. Apoptosis in cancer therapy: crossing the threshold. Cell 78(4):539-42.
Friedman SL, Shaulian E, Littlewood T, Resnitzky D, and Oren M. 1997. Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells. Oncogene 15(1):63-70.
Galati G and Brien P. J. O’. 2003. Cytoprotective and anticancer properties of coenzyme Q versus capsaicin. BioFactors. 18: 195-205.
Giuliano M, Schiraldi C, Marotta MR, Hugenholtz J, and De Rosa M. 2004. Expression of sulfolobus solfataricus | zh_TW |